Eli Lilly & Co. (NYSE: LLY) closed 11,7% higher as its experimental Alzheimer’s drug showed promise in a mid-stage clinical trial, boosting hopes for progress against the debilitating, progressive brain disorder. “This is clearly great news for the company and we expect the stock to trade toward our $200 PT and re-rate as a result of this potential new, commercial opportunity,” Cantor Fitzgerald analyst Louise Chen wrote in a research note.